Experimental Drug Dordaviprone Shows Promise Against Rare, Incurable Brain Tumor in Study
ONC201 (dordaviprone) displayed “well tolerated and durable and clinically meaningful efficacy in Histone 3 (H3) K27M mutant-diffuse midline glioma DMG.”
An experimental drug option, ONC201 (dordaviprone) could act as a new treatment for some patients with a rare incurable brain tumor, Histone 3 (H3) K27M mutant-diffuse midline glioma DMG.
In a study recently published in the Journal of Clinical Oncology, dordaviprone displayed “well tolerated and durable and clinically meaningful efficacy in [H3 K27M-DMG.]”
The (H3) K27M mutation is common DMG leads to a poor median overall survival (OS) of around 1 year, with prognosis varying based on genotype and age at diagnosis. These gliomas, primarily found in midline brain structures, often cannot be surgically removed.
Researchers across numerous health systems in the U.S examined the use of dordaviprone in DMG as the brain tumor has a dismal prognosis with no established effective therapy beyond radiation.
There were 50 patients (pediatric: 4; adult: 46) with recurrent H3 K27M–mutant DMG who received dordaviprone monotherapy in the clinical trial.
Eligible patients had a measurable disease and performance score (PS) more than 60 and were 90 days from radiation, with other brain tumors excluded.
The study assessed response rates, duration (DOR) and time to response (TTR) using Response Assessment in Neuro-Oncology (RANO) criteria in recurrent H3 K27M–mutant DMG patients receiving the monotherapy.
Results showed a 20.0% ORR (RANO- high-grade glioma (HGG)) with a median TTR of 8.3 months and a median DOR of 11.2 months.
The combined ORR by RANO-HGG or low-grade glioma (LGG) criteria was 30.0%. Corticosteroid dose reduction (more than 50%) occurred in 46.7%, and PS improvement in 20.6% of patients.
Grade 3 treatment-related adverse events were 20.0%, with fatigue being the most common (10%); no grade 4 events, deaths, or discontinuations occurred.
With limited effective therapies for H3 K27M–mutant DMG, the poor prognosis needs further research on dordaviprone’s efficacy.
A phase II study for newly diagnosed cases is ongoing.
The 2021 WHO disease definition suggests further research of dordaviprone in H3 K27me3 loss patients, regardless of H3 K27M mutation presence.Bottom of Form
Rutgers Cancer Institute Reviews Guidelines for Managing Blood Cancers During Pregnancy
April 8th 2025About 6% of pregnancy-related cancers are Hodgkin lymphoma, and 5% are non-Hodgkin lymphoma. Leukemias in pregnancy are rarer, accounting for 1 in 10,000 pregnancies. The most common pregnancy-related leukemias are acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and chronic myeloid leukemia (CML).
Read More
CAR T-Cell Therapy Cuts Costs, Reduces Treatment in Mantle Cell Lymphoma
March 13th 2025In a real-world study, researchers found this data by comparing treatment patterns, healthcare resource utilization, and costs between patients receiving CAR T-cell therapy and those treated with the non-CAR T standard of care.
Read More
Using the 'Pathway' Approach to Shorten the Time Between Cancer Diagnosis and Treatment
November 16th 2022In this episode of Tuning In to the C-Suite, Briana Contreras, editor with Managed Healthcare Executive spoke with Dr. Yuri Fesko, oncologist and vice president of Medical Affairs at Quest Diagnostics. In the conversation, Dr. Fesko addressed the ongoing issue of long gaps of times between receiving a diagnosis for a type of cancer and finally getting the treatment for it. Dr. Fesko shared the benefits a number of sectors receive when treating patients sooner and the steps to get there.
Listen
FDA Approves Tevimbra for Advanced Esophageal Cancer at $15,828 Per Month
March 5th 2025Esophageal squamous cell carcinoma accounts for approximately 90% of all esophageal cancer cases. Projections estimate that by 2040, there will be approximately 957,000 new cases of esophageal cancer worldwide, marking a nearly 60% increase from 2020, according to BeiGene.
Read More
